BIO-Europe® 2016: Inositec CEO on 2017 financing plans

December 6, 2016
Mattias Ivarsson, co-founder and CEO of Inositec, talks to Lucie Ellis, senior writer at Scrip, about the company's technology and progress since being founded in 2015. Inositec is developing innovative new drugs using its proprietary Inositune technology to adjust the properties of inositol phosphate analogs. Initially, the company will focus on two areas of high-unmet medical need: calcification disorders and Clostridium difficile infection (CDI). The company will carry out a series A financing round in 2017 in order to move its drug candidates into clinical studies.
Previous Video
BIO-Europe® 2016: Deciphera CEO on tackling cancer drug resistance
BIO-Europe® 2016: Deciphera CEO on tackling cancer drug resistance

Mike Ward, global director of content for Informa Pharma Intelligence, chats with Deciphera Pharmaceuticals...

Next Video
BIO-Europe® 2016: InflaRX CEO highlights pipeline goals
BIO-Europe® 2016: InflaRX CEO highlights pipeline goals

Neils Riedemann, founder and CEO of InflaRX, speaks to Lucie Ellis, senior writer at Scrip, about the compa...